Rockefeller Capital Management
ADAP

Rockefeller Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Rockefeller Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,166
Closed -$1.58K – 4670
2025
Q3 		$1.58K Buy
+12,166
New +$1.67K ﹤0.01% 4123
2023
Q1 		– Sell
-2,000
Closed -$2K – 1990
2022
Q4 		$2K Hold
2,000
– – ﹤0.01% 3529
2022
Q3 		$2K Hold
2,000
– – ﹤0.01% 3546
2022
Q2 		$3K Hold
2,000
– – ﹤0.01% 3608
2022
Q1 		$4K Hold
2,000
– – ﹤0.01% 3384
2021
Q4 		$7K Hold
2,000
– – ﹤0.01% 3124
2021
Q3 		$10K Hold
2,000
– – ﹤0.01% 2875
2021
Q2 		$8K Hold
2,000
– – ﹤0.01% 2851
2021
Q1 		$10K Hold
2,000
– – ﹤0.01% 2570
2020
Q4 		$10K Sell
2,000
-339
-14% -$1.84K ﹤0.01% 2224
2020
Q3 		$18K Buy
2,339
+339
+17% +$2.97K ﹤0.01% 1820
2020
Q2 		$20K Hold
2,000
– – ﹤0.01% 1680
2020
Q1 		$5K Hold
2,000
– – ﹤0.01% 1932
2019
Q4 		$2K Buy
+2,000
New +$2.13K ﹤0.01% 1900

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Rockefeller Capital Management's ADAP Position: Q4 2025 in Review

Rockefeller Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 12,166 shares — an estimated $1.58K sold.

Rockefeller Capital Management first reported a position in ADAP in Q4 2019 and held it in 14 quarters. The position peaked at $20K in Q2 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Rockefeller Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 12,166 Adaptimmune Therapeutics shares in Q4 2025, an estimated $1.58K.
  • Rockefeller Capital Management first reported a position in Adaptimmune Therapeutics in Q4 2019 and held it in 14 quarters.
  • Rockefeller Capital Management's Adaptimmune Therapeutics position peaked at $20K in Q2 2020.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Rockefeller Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.